|  |  | 

India Top Headlines

Potential Cancer Drug Repurposed for Covid-19 by DRDO, Dr. Reddy’s Gets DCGI Approval for Emergency Use | India News


HYDERABAD: A potential cancer drug repurposed for the treatment of Covid-19, 2-deoxy-D-glucose (2-DG), received the go-ahead from the Controller General of Medicines of India (DCGI) for emergency use as Complementary therapy for moderate to severe inpatients. Patients with Covid-19.
The drug’s anti-Covid-19 therapeutic application was developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a laboratory of the Defense Research and Development Organization (DRDO), in collaboration with leading pharmaceutical laboratories Dr. Reddy’s .
The medicine, which comes in a sachet in powder form, must be taken orally by dissolving it in water. The drug works by accumulating in cells infected by the virus and prevents virus growth by stopping viral synthesis and energy production.
“Its selective accumulation in virus-infected cells makes this drug unique. A higher proportion of patients treated with 2-DG showed negative conversion of RT-PCR in patients with Covid-19, ”said INMAS-DRDO.
According to INMAS-DRDO, the results of the clinical trial showed that the molecule helps in faster recovery of hospitalized patients and reduces their dependence on supplemental oxygen.
“In the second ongoing wave of the pandemic, a large number of patients face severe oxygen dependence and require hospitalization. This drug is expected to save precious lives due to the drug’s working mechanism in infected cells. By reducing the hospital stay of Covid-19 patients, it will also help reduce the burden on the country’s health infrastructure, “he explained.
Being a generic molecule and a glucose analog, it can be easily produced and abundantly available in the country, added INMAS-DRDO.
INMAS-DRDO scientists began research on drug reuse for Covid-19 in April 2020, during the first wave of the pandemic, and laboratory experiments were carried out with the help of the Center for Cellular and Molecular Biology (CCMB ), Hyderabad.
Phase II trials conducted in 110 patients in 17 hospitals found that patients who used the drug showed faster recovery and a difference of 2.5 days in terms of the median time to achieve normalization of certain vital parameters in comparison. with the standard of care (SoC).
The phase III clinical trial showed that a significantly higher proportion of patients taking the drug improved symptomatically and freed themselves from supplemental oxygen dependence (42% vs. 31%) by day 3 compared to SoC, indicating a early relief of oxygen dependence.
The phase III study was conducted in 220 patients during the period from December 2020 to March 2021 in 27 Covid hospitals in states such as Delhi, UP, West Bengal, Gujarat, Rajasthan, Maharashtra, Andhra Pradesh, Telangana, Karnataka and Tamil Nadu.

Reference page